Stock Surges On AL001 Phase II Trial Milestone

benzinga.com/news/25/05/45678189/alzamend-neuro-alzn-stock-surges-on-al001-phase-ii-trial-milestone

Shares of Alzamend Neuro Inc (NASDAQ:ALZN) surged 84% to $6.14 on Thursday morning following the announcement that the first patient has been dosed in the company’s Phase II clinical trial of AL001.
What To Know: The study, conducted in collaboration with Massachusetts General Hospital,…

This story appeared on benzinga.com, 2025-05-29 17:53:10.
The Entire Business World on a Single Page. Free to Use →